A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: Efficacy, safety and weight gain

Addiction

Volumn 104, Issue 2, 2009, Pages 266-276

  Rigotti, Nancy A ^a   Gonzales, David ^b   Dale, Lowell C ^c   Lawrence, Daniel ^d   Chang, Yuchiao ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Nicotine patch; Randomized controlled trial; Rimonabant; Smoking cessation

Indexed keywords

NICOTINE PATCH; PLACEBO; RIMONABANT;

ADD ON THERAPY; ADULT; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DREAMING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; NIGHTMARE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SMOKING CESSATION; SUICIDE ATTEMPT; TOBACCO DEPENDENCE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COUNSELING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; ODDS RATIO; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 58349105218     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2008.02454.x     Document Type: Article

References (32)

1. Mokdad A. H., Marks J. S., Stroup D. F., Gerberding J. L. Actual causes of death in the United States, 2000. JAMA 2004 291 : 1238 45.
2. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA : US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2004.
3. Centers for Disease Control and Prevention. Tobacco use. In : US Department of Health and Human Services, editor. Healthy People 2010: With Understanding and Improving Health and Objectives for Improving Health, 2nd edn, vol. 2. Washington, DC : US Government Printing Office 2000, p. 1 40.
4. Fiore M. C., Jaén C. R., Baker T. B., Bailey W. C., Benowitz N. L., Curry S. J. et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD : US Department of Health and Human Services, Public Health Service. 2008.
5. Jorenby D. E., Hays J. T., Rigotti N. A., Azoulay S., Watsky E. J., Williams K. E. et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006 296 : 56 63.
6. Gonzales D., Rennard S. I., Nides M., Oncken C., Azoulay S., Billing C. B. et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006 296 : 47 55.
7. US Department of Health and Human Services. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, GA : US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2000.
8. Williamson D. F., Madans J., Anda R. F., Kleinman J. C., Giovino G. A., Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991 324 : 739 45.
9. Perkins K. A. Issues in the prevention of weight gain after smoking cessation. Ann Behav Med 1994 16 : 46 52.
10. McBride C. M., French S. A., Pirie P. L., Jeffery R. W. Changes over time in weight concerns among women smokers engaged in the cessation process. Ann Behav Med 1996 18 : 273 9.
11. Hurt R. D., Sachs D. P., Glover E. D., Offord K. P., Johnston J. A., Dale L. C. et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997 337 : 1195 202.
12. Jorenby D. E., Leischow S. J., Nides M. A., Rennard S. I., Johnston J. A., Hughes A. R. et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999 340 : 685 91.
13. Le Foll B., Forget B., Aubin H. J., Goldberg S. R. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 2008 13 : 239 52.
14. Van Gaal L. F., Rissanen A. M., Scheen A. J., Ziegler O., Rossner S., RIO-Europe Study G. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 365 : 1389 97.
15. Pi-Sunyer F. X., Aronne L. J., Heshmati H. M., Devin J., Rosenstock J.,. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006 295 : 761 75.
16. Despres J. P., Golay A., Sjostrom L.,. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 353 : 2121 34.
17. Cohen C., Perrault G., Griebel G., Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2005 30 : 145 55.
18. Stead L., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008 1 : CD00146.
19. Hughes J. R., Stead L. F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007 1 : CD000031.
20. Cahill K., Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007 4 : CD005353.
21. Rumsfeld J. S., Nallamothu B. K. The hope and fear of rimonabant. JAMA 2008 299 : 1601 02.
22. Christensen R., Kristensen P. K., Bartels E. M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet 2007 370 : 1706 13.
23. Nissen S. E., Nicholls S. J., Wolski K. et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008 299 : 1547 60.
24. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 1991 86 : 1119 27.
25. Borrelli B., Mermelstein R. The role of weight concern and self-efficacy in smoking cessation and weight gain among smokers in a clinic-based cessation program. Addict Behav 1998 23 : 609 22.
26. Perkins K. A., Epstein L. H., Marks B. L., Stiller R. L., Jacob R. G. The effect of nicotine on energy expenditure during light physical activity. N Engl J Med 1989 320 : 898 903.
27. Perkins K. A., Epstein L. H., Stiller R. L., Marks B. L., Jacob R. G. Acute effects of nicotine on resting metabolic rate in cigarette smokers. Am J Clin Nutr 1989 50 : 545 50.
28. Allen S. S., Hatsukami D., Brintnell D. M., Bade T. Effect of nicotine replacement therapy on post-cessation weight gain and nutrient intake: a randomized controlled trial of postmenopausal female smokers. Addict Behav 2005 30 : 1273 80.
29. Dale L. C., Schroeder D. R., Wolter T. D., Croghan I. T., Hurt R. D., Offord K. P. Weight change after smoking cessation using variable doses of transdermal nicotine replacement. J Gen Intern Med 1998 13 : 9 15.
30. Marcus B. H., Albrecht A. E., King T. K., Parisi A. F., Pinto B. M., Roberts M. et al. The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial. Arch Intern Med 1999 159 : 1229 34.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC : American Psychiatric Association 1994.
32. Hughes J. R., Keely J. P., Niaura R. S., Ossip-Klein D. J., Richmond R. L., Swan G. E. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003 5 : 13 25.